Latest news

• AstraZeneca’s Imfinzi fails first-line bladder cancer test

  The failed study sets back AZ’s plans to expand Imfinzi into the first-line bladder cancer category, although it has already been granted an accelerated approval in the US for ... It also delays further competition to Roche’s rival PD-L1 inhibitor

• Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer

  Seattle Genetics and partner Astellas have reported positive results from an early clinical trial of their antibody drug conjugate Padcev in combination with Merck &Co/MSD’s Keytruda in first-line ... reached. Keytruda won approval for first-line

• Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer

  UC is a large market, accounting for around 90% of all bladder cancer diagnoses. ... Importantly for Merck KGaA and Pfizer, the drug is the first immunotherapy to achieve improvement in overall survival in the first-line setting in bladder cancer.

• Roche eyes filings for Tecentriq/Avastin combo in liver cancer

  plus anti-VEGF antibody Avastin (bevacizumab) or Bayer’s Nexavar (sorafenib), a standard first-line therapy for HCC. ... from other checkpoint inhibitors, and Roche is also eyeing other indications such as first-line bladder cancer.

• A look ahead to key trial readouts at ESMO

  Roche’s Tecentriq (atezolizumab) will feature in the Impassion 130 trial as a first-line treatment for triple negative breast cancer (TNBC) as a combination with nab-paclitaxel, with a positive ... It  will also have mid-stage data on the drug as a